Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. uri icon

Overview

abstract

  • In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections.

publication date

  • May 25, 2017

Research

keywords

  • Protein-Tyrosine Kinases
  • Pyrimidines

Identity

PubMed Central ID

  • PMC5572136

Scopus Document Identifier

  • 85019918895

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2017.05.004

PubMed ID

  • 28552326

Additional Document Info

volume

  • 31

issue

  • 6